Back to search
FDAFDA · Food and drugs·Recall number D-1149-2023

Sucralfate Oral Suspension 1g per 10mL, FOR ORAL ADMINISTRATION ONLY (414 mL bottle), Rx Only, Manufactured and Distributed by: VistaPharm, Inc. Largo, FL 33771, NDC 66689-305-16

Published September 20, 2023 · Recall initiated: August 30, 2023

Summary

FDA records drug Class II recall D-1149-2023, published September 20, 2023 and initiated August 30, 2023. Recalling firm: VistaPharm LLC; Status: Terminated; Reported quantity: 14,400 bottles; Lot: Lot #: 921100; Exp. 02/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent/Subpotent single ingredient Drug: Out of Specification Assay results

What to do

Voluntary: Firm initiated · Letter

Get an email if SUCRALFATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
SUCRALFATE
Manufacturer
VistaPharm LLC
Distributor
Distributed nationwide to 68 consignees in the U.S.
UPC
0366689305165
Lot
Lot #: 921100; Exp. 02/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sucralfate Oral Suspension 1g per 10mL, FOR ORAL ADMINISTRATION ONLY (414 mL bottle), Rx Only, Manufactured and Distributed by: VistaPharm, Inc. Largo, FL 33771, NDC 66689-305-16 recalled?

Yes. FDA published recall D-1149-2023 on September 20, 2023. Reported hazard: Superpotent/Subpotent single ingredient Drug: Out of Specification Assay results

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: SUCRALFATE. UPC: 0366689305165.